Cancer Research UK, Medivir deal

Cancer Research UK’s Cancer Research Technology (CRT) Ltd. commercialization and development arm partnered with Medivir to develop small molecules that target cell surface protein ADAM metallopeptidase domain 8 (ADAM8). Under the two-year deal, Medivir will have exclusive, worldwide rights to compounds developed under the deal. Medivir said the target has “shown promise” in treating cancer. ...